Insmed(INSM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

INSM Insmed

交易中 02-10 12:11:43 EST

150.43

+0.89

+0.59%

最高150.57	最低148.42	成交量41.85万
今开149.58	昨收149.54	日振幅1.44%
总市值317.96亿	流通市值291.82亿	总股本2.11亿
成交额6,256万	换手率0.22%	流通股本1.94亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"INSM","market":"US","secType":"STK","nameCN":"Insmed","latestPrice":150.425,"timestamp":1770743500903,"preClose":149.54,"halted":0,"volume":418546,"delay":0,"changeRate":0.005918148990236856,"floatShares":194000000,"shares":211374786,"eps":-6.219318,"marketStatus":"交易中","change":0.885,"latestTime":"02-10 12:11:43 EST","open":149.58,"high":150.57,"low":148.415,"amount":62556864.55764001,"amplitude":0.014411,"askPrice":150.61,"askSize":2,"bidPrice":150.24,"bidSize":577,"shortable":3,"etf":0,"ttmEps":-6.219318,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1770757200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":959832000000,"exchange":"NASDAQ","adjPreClose":149.54,"preHourTrading":{"tag":"盘前","latestPrice":149.93,"preClose":149.54,"latestTime":"09:29 EST","volume":130,"amount":19471.9096,"timestamp":1770733799088,"change":0.39,"changeRate":0.002608,"amplitude":0.01304},"postHourTrading":{"tag":"盘后","latestPrice":150.12,"preClose":149.54,"latestTime":"19:45 EST","volume":31255,"amount":4674795.37,"timestamp":1770684327464,"change":0.58,"changeRate":0.003879,"amplitude":0.003879},"volumeRatio":0.464935,"impliedVol":0.526,"impliedVolPercentile":0.506},"requestUrl":"/m/hq/s/INSM","defaultTab":"news","newsList":[{"id":"1179116674","title":"Insmed 2025年初步营收6.06亿美元，同比增长67%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179116674","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179116674?lang=zh_cn&edition=full","pubTime":"2026-01-09 21:06","pubTimestamp":1767964011,"startTime":"0","endTime":"0","summary":"1月9日，生物制药公司Insmed盘前涨超11%，此前该公司宣布了2025年强劲的初步收入结果，其中BRINSUPRI成功上市和ARIKAYCE销售超出预期成为亮点。Insmed 2025年初步未经审计的总收入达到6.064亿美元，较2024年增长67%，超过了5.22亿美元的市场共识预期。公司预计2026年ARIKAYCE全球收入将在4.5亿至4.7亿美元之间。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"87f58df0cea45f9dc7f6df99dc1f4be0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Insmed 2025年初步营收6.06亿美元，同比增长67%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM"],"gpt_icon":1},{"id":"1159401717","title":"Insmed股票在盘前交易中下跌20.1%，因公司中期研究失败后停止鼻窦药物开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1159401717","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159401717?lang=zh_cn&edition=full","pubTime":"2025-12-18 18:30","pubTimestamp":1766053814,"startTime":"0","endTime":"0","summary":"Insmed股票在盘前交易中下跌20.1%，因公司中期研究失败后停止鼻窦药物开发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f9f3169eeaffd188a4d97d9b846e92ea","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0320765992.SGD","LU0053671581.USD","INSM","BK4139","LU0889565916.HKD"],"gpt_icon":0},{"id":"1188873548","title":"美股夜盘 | 美光科技绩后涨超8%，大麻股CGC涨超13%；INSM暴跌18%，CART跌近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188873548","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188873548?lang=zh_cn&edition=full","pubTime":"2025-12-18 09:05","pubTimestamp":1766019931,"startTime":"0","endTime":"0","summary":"12月18日，美股夜盘时段，$美光科技(MU)$涨超8%，芯片需求旺盛，业绩与指引双双“爆表”；受此消息影响，存储概念股集体走高，$SanDisk Corp(SNDK)$涨超5%，$西部数据(WDC)$涨超2%。大麻股夜盘上涨，$Canopy Growth(CGC)$涨超13%，Tilray涨超5%。报道称特朗普拟于周四签署行政令重新归类大麻；医疗用品供应商Medline夜盘跌超2%，其上市首日股价涨超40%；","market":"us","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CART","BK4554","MDLN","BK4553","BK4543","BK4527","MU","BK4605","BK4588","BK4141","TLRY","BK4579","BK4533","INSM","BK4585","BK4512","BK4575","BK4566","BK4532"],"gpt_icon":0},{"id":"1173952258","title":"Insmed收购二期临床准备的单克隆抗体 以应对潜在的呼吸系统及免疫与炎症相关指示","url":"https://stock-news.laohu8.com/highlight/detail?id=1173952258","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173952258?lang=zh_cn&edition=full","pubTime":"2025-12-18 05:03","pubTimestamp":1766005391,"startTime":"0","endTime":"0","summary":"Insmed收购二期临床准备的单克隆抗体 以应对潜在的呼吸系统及免疫与炎症相关指示","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4139","INSM","LU0889565916.HKD","LU0320765992.SGD","LU0053671581.USD"],"gpt_icon":0},{"id":"1168222595","title":"Insmed Inc - Brensocatib在CRSSNP的2B期Birch研究未达到主要或次要疗效指标","url":"https://stock-news.laohu8.com/highlight/detail?id=1168222595","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168222595?lang=zh_cn&edition=full","pubTime":"2025-12-18 05:03","pubTimestamp":1766005391,"startTime":"0","endTime":"0","summary":"Insmed Inc - Brensocatib在CRSSNP的2B期Birch研究未达到主要或次要疗效指标","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM","LU0320765992.SGD","LU0889565916.HKD","BK4139","LU0053671581.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"1131212462","title":"纳斯达克公司：阿尔尼拉姆制药、Ferrovial、Insmed、单片电源系统、希捷科技、西部数据将被纳入纳斯达克100指数","url":"https://stock-news.laohu8.com/highlight/detail?id=1131212462","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131212462?lang=zh_cn&edition=full","pubTime":"2025-12-13 09:09","pubTimestamp":1765588155,"startTime":"0","endTime":"0","summary":"纳斯达克公司：阿尔尼拉姆制药、Ferrovial、Insmed、单片电源系统、希捷科技、西部数据将被纳入纳斯达克100指数","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0edbc198404a72334f079a67157af149","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0056508442.USD","LU1642822529.SGD","LU0882574055.USD","MPWR","LU0672654240.SGD","IE00BN0W2W23.USD","LU1235294995.USD","LU1823568750.SGD","SG9999014013.SGD","LU2210149790.SGD","LU2322448957.HKD","LU1992135472.HKD","LU1267930730.SGD","LU0889565916.HKD","LU0320765992.SGD","LU0444971666.USD","LU1815336760.USD","IE00BN0W2T93.GBP","LU1861220033.SGD","LU1861215975.USD","LU0109391861.USD","LU0353189680.USD","LU0114720955.EUR","ALNY","WDC","BK4588","BK4141","LU0109394709.USD","BK4512","INSM","LU0708995401.HKD","IE00BD6J9T35.USD","LU1069347547.HKD","IE00B19Z9Z06.USD","NDAQ","LU0476273544.USD","LU0444973449.USD","IE00B3QW5Z07.USD","BK4548","LU1670627923.USD","LU0006061336.USD","IE00B64PRP62.GBP","LU2210150020.SGD","LU2250418816.HKD","SG9999014005.SGD","LU0353189763.USD","SG9999014021.USD","LU0203345920.USD","LU2322448791.USD","LU1046421795.USD","BK4112","IE00B894F039.SGD","LU2360107168.USD","STX","BK4170","LU0274383776.USD","BK4139","LU1852331112.SGD","LU1035773651.USD","LU0081259029.USD","IE00B19Z9P08.USD","LU2095319765.USD","LU0957808578.USD","LU2290526834.HKD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU0314104364.USD","LU2360106780.USD","LU0203347892.USD","LU0320765059.SGD","LU2087625088.SGD","LU2089985449.USD","SG9999014039.USD","LU2473716301.USD","LU2272731865.HKD","LU2272731782.SGD","BK4585","LU1992135399.USD","IE00BGHQF748.EUR","LU1670628061.USD","LU2272731600.USD","LU0053671581.USD","LU2931357623.SGD"],"gpt_icon":0},{"id":"1197329900","title":"Insmed将于2026年初与欧盟当局互动，确保合格患者获取Brinsupri","url":"https://stock-news.laohu8.com/highlight/detail?id=1197329900","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197329900?lang=zh_cn&edition=full","pubTime":"2025-11-19 00:03","pubTimestamp":1763481792,"startTime":"0","endTime":"0","summary":"Insmed将于2026年初与欧盟当局互动，确保合格患者获取Brinsupri","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0320765992.SGD","INSM","LU0109394709.USD","BK4139","LU0053671581.USD"],"gpt_icon":0},{"id":"1121135608","title":"欧洲委员会批准Brinsupri™（Brensocatib）作为欧盟唯一获批的非囊性纤维化支气管扩张症治疗药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1121135608","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121135608?lang=zh_cn&edition=full","pubTime":"2025-11-19 00:01","pubTimestamp":1763481679,"startTime":"0","endTime":"0","summary":"欧洲委员会批准Brinsupri™（Brensocatib）作为欧盟唯一获批的非囊性纤维化支气管扩张症治疗药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM","LU0053671581.USD","LU0109394709.USD","BK4139","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2576055837","title":"EMA十月药品审评会议：赛诺菲(SNY.US)、Insmed(INSM.US)等公司新药获上市推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2576055837","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576055837?lang=zh_cn&edition=full","pubTime":"2025-10-17 21:29","pubTimestamp":1760707780,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，在本周召开的会议上，欧洲药品管理局的专家小组对赛诺菲与Insmed的两款新药做出了推荐在该地区上市的积极意见。除了推荐新药获批外，该委员会还否决了赛诺菲的一款新药，并推荐了8项新的药品适应症扩展申请。赛诺菲表示，这一决定基于该公司关键的LUNA 3期临床试验。该公司表示，CHMP的这一决定令人失望，并将寻求对该决定进行重新审查。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356643.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SNY","BK4588","INSM","LU0320765992.SGD","LU0109394709.USD","BK4081","EMA","LU0053671581.USD","BK4139","BK4585","LU0889565916.HKD","BK4007","IE00BFXG1179.USD"],"gpt_icon":0},{"id":"1135371274","title":"CHMP建议欧盟批准Brinsupri™（Brensocatib）用于非囊性纤维化支气管扩张症的治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1135371274","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135371274?lang=zh_cn&edition=full","pubTime":"2025-10-17 19:01","pubTimestamp":1760698885,"startTime":"0","endTime":"0","summary":"CHMP建议欧盟批准Brinsupri™（Brensocatib）用于非囊性纤维化支气管扩张症的治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0889565916.HKD","LU0053671581.USD","BK4139","LU0320765992.SGD","INSM"],"gpt_icon":0},{"id":"1165253215","title":"高盛将沃尔玛、瓦莱罗能源加入9月“确信名单”，还有这些公司入选","url":"https://stock-news.laohu8.com/highlight/detail?id=1165253215","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165253215?lang=zh_cn&edition=full","pubTime":"2025-09-03 13:45","pubTimestamp":1756878304,"startTime":"0","endTime":"0","summary":"高盛在9月的确信名单中新增了四只股票，其中既包括美国一些最知名的品牌，也有部分能源股。不过，高盛指出，移出名单并不一定意味着其对相关股票的基本投资评级发生了改变。高盛根据营收增长、当前股息收益率等多重指标，认为这些公司具有投资吸引力。截至目前，该股年内已上涨 8%。高盛对沃尔玛的“买入”评级与华尔街整体观点一致。高盛认为，其股价还有 7% 的上行空间。","market":"us","thumbnail":"https://community-static.tradeup.com/news/ebd93ab0fd3bcb1f3363cb69f435ed88","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/ebd93ab0fd3bcb1f3363cb69f435ed88"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"高盛将沃尔玛、瓦莱罗能源加入9月“确信名单”，还有这些公司入选","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WMT","CDNS","VLO","GEV","MCD","INSM","VNOM"],"gpt_icon":1},{"id":"2562083099","title":"Bybit 上线 BLSH、INSM 和 TME 股票 CFD","url":"https://stock-news.laohu8.com/highlight/detail?id=2562083099","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562083099?lang=zh_cn&edition=full","pubTime":"2025-08-28 15:20","pubTimestamp":1756365602,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，Bybit 现已上线 BLSH、INSM 和 TME 股票 CFD 交易，用户可前往平台进行交易。 ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2201486","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","IE00B12V2V27.USD","BK4108","IE00BYQNZ168.SGD","BK4563","BK4535","BK4509","IE00BYTNYN87.SGD","LU2039709279.SGD","BK4531","INSM","BK4526","LU0889565916.HKD","SG9999011746.SGD","LU0456842615.SGD","LU0053671581.USD","LU0359202008.SGD","BK4139","BK4112","BK4552","LU1023057109.AUD","BK4548","LU0320765992.SGD","BK4565","01698","BK4571","LU0359201612.USD","BLSH","TME"],"gpt_icon":0},{"id":"2514113720","title":"Insmed(INSM.US)获加拿大皇家银行首次覆盖，给予优于大市评级, 目标价100.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514113720","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514113720?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:23","pubTimestamp":1740500610,"startTime":"0","endTime":"0","summary":"Insmed(INSM.US)获加拿大皇家银行首次覆盖，给予优于大市评级, 目标价100.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/26002348385754.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["INSM"],"gpt_icon":0},{"id":"2513875615","title":"Insmed Incorporated2024财年实现净利润-9.14亿美元，同比减少21.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513875615","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513875615?lang=zh_cn&edition=full","pubTime":"2025-02-24 00:00","pubTimestamp":1740326449,"startTime":"0","endTime":"0","summary":"2月24日，Insmed Incorporated公布财报，公告显示公司2024财年净利润为-9.14亿美元，同比减少21.87%；其中营业收入为3.64亿美元，同比增加19.34%，每股基本收益为-5.57美元。从资产负债表来看，Insmed Incorporated总负债17.40亿美元，其中短期债务16.50百万美元，资产负债比为1.17，流动比率为5.45。机构评级：截至2025年2月24日，当前有15家机构对Insmed Incorporated目标价做出预测，其中目标均价为96.93美元，其中最低目标价为89.00美元，最高目标价为108.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000118a250ce02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000118a250ce02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INSM"],"gpt_icon":0},{"id":"2513691213","title":"Truist Securities：维持Insmed(INSM.US)评级，由买入调整至买入评级, 目标价由105.00美元调整至108.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513691213","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513691213?lang=zh_cn&edition=full","pubTime":"2025-02-22 01:41","pubTimestamp":1740159669,"startTime":"0","endTime":"0","summary":"Truist Securities：维持Insmed(INSM.US)评级，由买入调整至买入评级, 目标价由105.00美元调整至108.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/22014148321070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["INSM"],"gpt_icon":0},{"id":"1119035536","title":"异动解读 | 盘中狂泻5.11%!Insmed财报营收增长放缓、亏损扩大引发股价大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1119035536","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119035536?lang=zh_cn&edition=full","pubTime":"2025-02-20 22:37","pubTimestamp":1740062235,"startTime":"0","endTime":"0","summary":"在今日盘中交易中,生物制药公司Insmed股价大跌5.11%,引发了市场广泛关注。据分析,这与公司2024年第四季度财报表现不佳有很大关系。\n\n具体来看,Insmed上一季度销售额虽然达到1.0444亿美元、高于预期,但同比增长仅为24.79%,增速明显放缓。更为重要的是,Insmed当季每股亏损高达1.32美元,远高于分析师预期的1.17美元亏损。\n\n营收增长放缓加之亏损扩大,令投资者对Insmed的业务前景和盈利能力产生质疑,从而引发公司股价在盘中大幅下跌。Insmed面临着业绩增长乏力、成本控制不佳等一系列问题,当务之急是尽快扭转局面、实现盈利,从而重拾投资者信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["INSM"],"gpt_icon":0},{"id":"1148282852","title":"Insmed 2024年第四季度每股亏损$(1.32)，低于$(1.17)的预期；销售额$1.0444亿，高于$1.0179亿的预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1148282852","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148282852?lang=zh_cn&edition=full","pubTime":"2025-02-20 20:09","pubTimestamp":1740053345,"startTime":"0","endTime":"0","summary":"Insmed  报告了季度每股亏损$，比分析师共识预期的$低了12.82%。这一亏损相比去年同期的每股亏损$减少了3.13%。公司报告的季度销售额为$1.0444亿，高于分析师共识预期的$1.0179亿，增长了2.60%。以上内容来自Benzinga Earnings专栏，原文如下：$Insmed$  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 12.82 percent. This is a 3.13 percent decrease over losses of $ per share from the same period last year.  The company reported quarterly sales of $104.44 million which beat the analyst consensus estimate of $101.79 million by 2.60 percent.  This is a 24.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Insmed 2024年第四季度每股亏损$(1.32)，低于$(1.17)的预期；销售额$1.0444亿，高于$1.0179亿的预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM"],"gpt_icon":1},{"id":"2509774987","title":"小摩：维持Insmed(INSM.US)评级，由增持调整至增持评级, 目标价由83.00美元调整至92.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509774987","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509774987?lang=zh_cn&edition=full","pubTime":"2025-02-08 05:21","pubTimestamp":1738963318,"startTime":"0","endTime":"0","summary":"小摩：维持Insmed(INSM.US)评级，由增持调整至增持评级, 目标价由83.00美元调整至92.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/08052148031920.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["INSM"],"gpt_icon":0},{"id":"2509274305","title":"大摩：维持Insmed(INSM.US)评级，由增持调整至增持评级, 目标价由85.00美元调整至90.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509274305","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509274305?lang=zh_cn&edition=full","pubTime":"2025-02-06 22:22","pubTimestamp":1738851741,"startTime":"0","endTime":"0","summary":"大摩：维持Insmed(INSM.US)评级，由增持调整至增持评级, 目标价由85.00美元调整至90.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/06222248001920.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["INSM"],"gpt_icon":0},{"id":"2505205840","title":"Insmed Incorporated盘中异动 股价大涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505205840","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505205840?lang=zh_cn&edition=full","pubTime":"2025-01-22 00:20","pubTimestamp":1737476447,"startTime":"0","endTime":"0","summary":"北京时间2025年01月22日00时20分，Insmed Incorporated股票出现异动，股价急速上涨5.09%。Insmed Incorporated股票所在的生物技术行业中，整体涨幅为1.61%。其相关个股中，Channel Therapeutics Corporation、Dogwood Therapeutics, Inc.、Genelux Corporation涨幅较大，Dogwood Therapeutics, Inc.、Channel Therapeutics Corporation、Dermata Therapeutics, Inc.较为活跃，换手率分别为757.13%、475.49%、182.30%，振幅较大的相关个股有Channel Therapeutics Corporation、Klotho Neurosciences Inc C/Wts 21/06/2029 、Dogwood Therapeutics, Inc.，振幅分别为96.32%、41.33%、38.48%。Insmed Incorporated公司简介：Insmed Inc是一家全球性的生物制药公司，致力于改善严重和罕见疾病患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122002047986e474b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122002047986e474b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","LU0320765992.SGD","INSM","LU0109394709.USD","BK4139","LU0053671581.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.insmed.com","stockEarnings":[{"period":"1week","weight":-0.0288},{"period":"1month","weight":-0.1502},{"period":"3month","weight":-0.2279},{"period":"6month","weight":0.2171},{"period":"1year","weight":0.8704},{"period":"ytd","weight":-0.1408}],"compareEarnings":[{"period":"1week","weight":-0.0021},{"period":"1month","weight":-0.0002},{"period":"3month","weight":0.016},{"period":"6month","weight":0.0761},{"period":"1year","weight":0.1551},{"period":"ytd","weight":0.0176}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Insmed Incorporated是一家生物制药公司，专注于研发吸入疗法为患者对抗危及生命的肺部疾病。公司主打产品ARIKACE和阿米卡星脂质体吸入剂是一种吸入的抗生疗法，证明抗感染药在治疗肺部重感染疾病时能提升该疗法的效果，安全性阿和便利性。公司于1999年11月29日在英联邦弗吉尼亚州成立。","yearOnYearQuotes":[{"month":1,"riseRate":0.457143,"avgChangeRate":0.066603},{"month":2,"riseRate":0.4,"avgChangeRate":0.075472},{"month":3,"riseRate":0.371429,"avgChangeRate":-0.053836},{"month":4,"riseRate":0.4,"avgChangeRate":0.04767},{"month":5,"riseRate":0.4,"avgChangeRate":0.067566},{"month":6,"riseRate":0.542857,"avgChangeRate":0.027147},{"month":7,"riseRate":0.485714,"avgChangeRate":0.004271},{"month":8,"riseRate":0.4,"avgChangeRate":-0.021648},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032075},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.015562},{"month":11,"riseRate":0.657143,"avgChangeRate":0.105034},{"month":12,"riseRate":0.457143,"avgChangeRate":0.040841}],"exchange":"NASDAQ","name":"Insmed","nameEN":"Insmed"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Insmed(INSM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Insmed(INSM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Insmed,INSM,Insmed股票,Insmed股票老虎,Insmed股票老虎国际,Insmed行情,Insmed股票行情,Insmed股价,Insmed股市,Insmed股票价格,Insmed股票交易,Insmed股票购买,Insmed股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Insmed(INSM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Insmed(INSM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}